Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates

Company Performance - Myomo, Inc. reported a quarterly loss of $0.08 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.10 per share a year ago [1] - The company posted revenues of $9.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.29%, compared to revenues of $3.75 million in the same quarter last year [2] - Over the last four quarters, Myomo has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Stock Outlook - Myomo shares have declined approximately 25.9% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.06 on revenues of $10.35 million, and for the current fiscal year, it is -$0.07 on revenues of $50.95 million [7] Industry Context - The Medical - Products industry, to which Myomo belongs, is currently ranked in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Myomo's stock performance [5][6]